5 nM in cell-free assays, modestly potent to Bmx, CSK, FGR, BRK, HCK, less potent to EGFR, Yes, ErbB2, JAK3, etc. BTK inhibitor with an Collagen induced arthritis model of 0.
46 nM for the purified Btk. BTK C481S and C481T variants show resistance to ibrutinib. COS-7 cells were transfected with wild-type BTK or the two variants. Thirty-six hours post transfection, the cells were serum starved and treated with ibrutinib overnight followed by activation with serum and pervanadate for 5 min at room temperature. The cell lysates were immunoblotted for pY223 BTK and pY753 PLCγ2.
Identification of Btk as a potent kinase for WIP tyrosine phosphorylation. Total protein lysates were prepared from THP-1 cells that were stably transfected with wild-type WIP-EGFP and treated with PCI-32765 at the concentration specified on the blots for 2h before pervanadate treatment for 30 min. 2 and AKT, but not BTK, was inhibited in sensitive but not resistant MCL cells. Western blotting of BTK phosphorylation. Effect of Ibrutinib on CLEC-2-mediated platelet activation and signaling in humans. BTK is expressed by malignant plasma cells and ibrutinib induces cytotoxicity in MM patient cells.
BTK mRNA and protein expression in control B-cells and MM patient cells and MM cell lines as measured by real-time PCR and Western blotting. Ibrutinib induces increased cytotoxicity in combination with lenalidomide and bortezomib in MM patient cells. Ibrutinib downregulates anti-apoptotic proteins and induces caspase mediated apoptosis in MM cells. Cell lines were exposed to 0, 50 and 150 mM Ibrutinib for 4 h. TCF3-rearranged MHH-CALL3 compared with non-TCF3-rearranged Nalm6 and MHH-CALL4 cell lines.
Actin served as a loading control. See Supplementary Materials and methods document for more information. Ibrutinib shows the potent and irreversible inhibitory effect and selectivity for Btk enzymatic activity. In BCR pathway-activated DOHH2 cell line, Ibrutinib inhibits autophosphorylation of Btk, phosphorylation of Btk’s physiological substrate PLCγ, and phosphorylation of further downstream kinase, ERK with IC50 of 11 nM, 29 nM and 13 nM, respectively. In addition, Ibrutinib induces cell death depending on caspase pathway activation and antagonizes the ability of CLL cells to proliferate after TLR signaling.
A recent study shows that Ibrutinib inhibits BCR-activated primary B cell proliferation with IC50 of 8 nM and results in inhibition of TNFα, IL-1β and IL-6 production in primary monocytes with IC50 of 2. P-ATP, Ibrutinib, and substrate . Assays are performed at Reaction Biology. 48 hours with different concentrations of Ibrutinib, or vehicle control. MTT reagent is then added, and plates are incubated for an additional 20 hours before washing with protamine sulfate in phosphate-buffered saline.
Dimethyl sulfoxide is added, and absorbance is measured by spectrophotometry at 540 nm in a Labsystems plate reader. Data are analyzed with Expo-ADC32 software package. Results are expressed as the percentage of total positive cells over untreated control. Experiments examining caspase-dependent apoptosis includes the addition of 100μM Z-VAD. Ibrutinib is dissolved in DMSO.
Proc Natl Acad Sci U S A. For best results, use promptly after mixing. Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. Calculate the dilution required to prepare a stock solution. Tip: Chemical formula is case sensitive. To calculate molar mass of a chemical compound, please enter its chemical formula and click ‘Calculate’.